

#### Calendar No. 364

115TH CONGRESS 2D SESSION

## H. R. 1660

#### IN THE SENATE OF THE UNITED STATES

January 19, 2018
Received; read twice and referred to the Committee on Foreign Relations
March 22, 2018
Reported by Mr. Corker, without amendment

### AN ACT

- To direct the Administrator of the United States Agency for International Development to submit to Congress a report on the development and use of global health innovations in the programs, projects, and activities of the Agency.
  - 1 Be it enacted by the Senate and House of Representa-
  - 2 tives of the United States of America in Congress assembled,
  - 3 SECTION 1. SHORT TITLE.
  - 4 This Act may be cited as the "Global Health Innova-
  - 5 tion Act of 2017".

#### 1 SEC. 2. ANNUAL REPORT.

2	(a) In General.—Not later than 180 days after the					
3	date of the enactment of this Act, and annually thereafter					
4	for a period of 4 years, the Administrator of the United					
5	States Agency for International Development shall submit					
6	to Congress a report on the development and use of global					
7	health innovations in the programs, projects, and activities					
8	of the Agency.					
9	(b) Matters To Be Included.—The report re-					
10	quired by subsection (a) shall include the following:					
11	(1) A description of—					
12	(A) the extent to which global health inno-					
13	vations described in subsection (a) include					
14	drugs, diagnostics, devices, vaccines, electronic					
15	and mobile health technologies, and related be-					
16	havior change and service delivery innovations;					
17	(B) how innovation has advanced the					
18	Agency's commitments to achieving an HIV/					
19	AIDS-free generation, ending preventable child					
20	and maternal deaths, and protecting commu-					
21	nities from infectious diseases, as well as					
22	furthered by the Global Health Strategic					
23	Framework;					
24	(C) how goals are set for health product					
25	development in relation to the Agency's health-					

1	related goals and how progress and impact are
2	measured towards those goals;
3	(D) how the Agency's investments in inno-
4	vation relate to its stated goals; and
5	(E) progress made towards health product
6	development goals.
7	(2) How the Agency, both independently and
8	with partners, donors, and public-private partner-
9	ships, is—
10	(A) leveraging United States investments
11	to achieve greater impact in health innovation;
12	(B) engaging in activities to develop, ad-
13	vance, and introduce affordable, available, and
14	appropriate global health products; and
15	(C) scaling up appropriate health innova-
16	tions in the development pipeline.
17	(3) A description of collaboration and coordina-
18	tion with other Federal departments and agencies,
19	including the Centers for Disease Control and Pre-
20	vention, in support of global health product develop-
21	ment, including a description of how the Agency is
22	working to ensure critical gaps in product develop-
23	ment for global health are being filled.
24	(4) A description of how the Agency is coordi-
25	nating and aligning global health innovation activi-

- 1 ties between the Global Development Lab, the Cen-
- 2 ter for Accelerating Innovation and Impact, and the
- 3 Bureau for Global Health.

# Calendar No. 364

115TH CONGRESS H. R. 1660

# AN ACT

To direct the Administrator of the United States Agency for International Development to submit to Congress a report on the development and use of global health innovations in the programs, projects, and activities of the Agency.

March 22, 2018

Reported without amendment